L&S Venture Capital

L&S Venture Capital is a Seoul, South Korea-based venture capital firm founded in 2006, managing approximately 501.8 billion won, equivalent to roughly $400 million USD. The firm has a team of 15 including 6 partners, investing from incubation and seed stages through early and expansion rounds, with typical check sizes of $1 million to $5 million at Series A. L&S leads rounds and has one of the most impressive IPO track records among Korean venture firms, with 26 portfolio IPOs and 3 acquisitions across 90 total investments. The firm's investment focus spans semiconductors, materials, components and equipment, artificial intelligence, IoT, cloud computing, big data, mobile and network infrastructure, and e-healthcare. Notable IPO exits include INNOSPACE (space launch technology, KRX listing in July 2024 at a $293 million market capitalization), E8IGHT (KRX, $142 million market capitalization), SillaJen (oncolytic immunotherapy biopharmaceutical), and PharmAbcine (antibody therapeutics). The most notable acquisition was Panax Etec, sold to Dongwha Enterprise in August 2019 for $97.1 million. The most recent investment was AIRS at Series A in March 2025, with recent activity also including Align AI and Ettifos. L&S also invests in Israel alongside its primary focus on the Seoul, Gyeonggi, and Chungnam regions of Korea. L&S provides financial, business, and strategic support to portfolio companies across smart IT, green energy, fusion technology, and media content sectors. The firm's sustained 90-investment track record and 26-IPO exit history reflect a deep integration with the Korean capital markets ecosystem and a proven ability to guide technology companies through public listing processes.